HUE042792T2 - Eljárások és anyagok hematológiai, rosszindulatú betegségek kezelésére - Google Patents

Eljárások és anyagok hematológiai, rosszindulatú betegségek kezelésére

Info

Publication number
HUE042792T2
HUE042792T2 HUE14860231A HUE14860231A HUE042792T2 HU E042792 T2 HUE042792 T2 HU E042792T2 HU E14860231 A HUE14860231 A HU E14860231A HU E14860231 A HUE14860231 A HU E14860231A HU E042792 T2 HUE042792 T2 HU E042792T2
Authority
HU
Hungary
Prior art keywords
materials
methods
hematological malignancies
treating hematological
treating
Prior art date
Application number
HUE14860231A
Other languages
English (en)
Inventor
Ayalew Tefferi
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of HUE042792T2 publication Critical patent/HUE042792T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/22Haematology
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
HUE14860231A 2013-11-06 2014-11-05 Eljárások és anyagok hematológiai, rosszindulatú betegségek kezelésére HUE042792T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900854P 2013-11-06 2013-11-06
US201361904195P 2013-11-14 2013-11-14

Publications (1)

Publication Number Publication Date
HUE042792T2 true HUE042792T2 (hu) 2019-07-29

Family

ID=53042029

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14860231A HUE042792T2 (hu) 2013-11-06 2014-11-05 Eljárások és anyagok hematológiai, rosszindulatú betegségek kezelésére

Country Status (16)

Country Link
US (1) US11123359B2 (hu)
EP (2) EP3065828B1 (hu)
JP (1) JP6532478B2 (hu)
AU (1) AU2014346840B2 (hu)
CA (1) CA2929809C (hu)
CY (1) CY1122229T1 (hu)
DK (1) DK3065828T3 (hu)
ES (1) ES2717777T3 (hu)
HR (1) HRP20190538T1 (hu)
HU (1) HUE042792T2 (hu)
LT (1) LT3065828T (hu)
PL (1) PL3065828T3 (hu)
PT (1) PT3065828T (hu)
RS (1) RS58659B1 (hu)
SI (1) SI3065828T1 (hu)
WO (1) WO2015069758A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
BR112020001749A2 (pt) * 2017-07-28 2020-07-21 Geron Corporation métodos de tratamento da síndrome mielodisplásica
CN112770783A (zh) * 2018-07-31 2021-05-07 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
KR20230041707A (ko) * 2020-07-17 2023-03-24 제론 코포레이션 피하 텔로머라제 억제제 조성물 및 이의 사용 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2898887T1 (sl) * 2006-10-30 2019-01-31 Geron Corporation Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka
EP2534261B1 (en) * 2010-02-12 2016-11-30 QIAGEN Marseille Asxl1 as a new diagnostic marker of myeloid neoplasms
EP2771010A4 (en) 2011-10-19 2015-04-01 Pharmacyclics Inc USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK)
EP2771294B1 (en) * 2011-10-25 2017-12-13 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2013151983A1 (en) * 2012-04-02 2013-10-10 The Cleveland Clinic Foundation Methods for predicting the prognosis of a subject with a myeloid malignancy
US9375485B2 (en) * 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
JP6433911B2 (ja) * 2012-12-07 2018-12-05 ジェロン・コーポレーションGeron Corporation 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
CN112770783A (zh) 2018-07-31 2021-05-07 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法

Also Published As

Publication number Publication date
EP3065828B1 (en) 2019-01-09
JP2016537423A (ja) 2016-12-01
WO2015069758A1 (en) 2015-05-14
EP3539547A1 (en) 2019-09-18
LT3065828T (lt) 2019-04-10
CY1122229T1 (el) 2020-11-25
PT3065828T (pt) 2019-04-01
PL3065828T3 (pl) 2019-06-28
DK3065828T3 (en) 2019-04-15
EP3065828A4 (en) 2017-07-19
AU2014346840B2 (en) 2020-02-06
CA2929809C (en) 2022-05-17
SI3065828T1 (sl) 2019-04-30
ES2717777T3 (es) 2019-06-25
RS58659B1 (sr) 2019-05-31
EP3065828A1 (en) 2016-09-14
US11123359B2 (en) 2021-09-21
JP6532478B2 (ja) 2019-06-19
HRP20190538T1 (hr) 2019-05-17
US20160287625A1 (en) 2016-10-06
AU2014346840A1 (en) 2016-06-02
CA2929809A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
IL281058B1 (en) Compositions and methods for treating anemia
IL245778A0 (en) Methods and preparations for the treatment of hemophilia
IL245281A0 (en) Methods and preparations for the treatment of cancer
RS62788B1 (sr) Anti-lag-3 antitela za lečenje hematoloških maligniteta
EP2992041A4 (en) METHOD FOR TREATING LIGNOCELLULOSE MATERIALS
GB201420103D0 (en) Treating particles
EP2950884A4 (en) COMPOSITIONS AND METHOD FOR TREATING SURFACES
IL244118A0 (en) Compounds and methods for the treatment of chronic urticaria
HRP20190538T1 (hr) Postupci i materijali za liječenje hematoloških malignosti
IL244353A0 (en) Compounds and use for cancer treatment
HK1225647A1 (zh) 用於治療癌症的組合物和方法
EP2825693A4 (en) METHOD AND MATERIALS FOR THE TREATMENT OF CANCER
GB201411429D0 (en) Methods for monitoring treatment response and relapse in ovarian cancer
IL246069A0 (en) Preparations and methods for the treatment of malignant blood diseases
EP3065755A4 (en) Methods for treating hematological malignancies
IL246185A0 (en) Methods and compositions for treating dysregulation in systems
GB2519829B (en) Methods for monitoring treatment response and relapse in breast cancer
EP2971044A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
ZA201408732B (en) Composition and methods for treating wounds
GB201314922D0 (en) Materials and methods for treating ARID1A deficent Cancer
GB201319951D0 (en) Treating Particle